Robert Weigle

Robert Weigle

Robert K. Weigle is the CEO of Prime Genomics, a saliva-based diagnostics company utilizing Genomics. Mr Weigle is also currently an executive in residence with DigitalDX, a venture capital firm. Mr. Weigle was formerly CEO and a director of Benvenue Medical, leading a commercial launch of first-generation devices in two distinct markets, treatment of compression fractures in the spine and treatment of degenerative disc disease. Mr. Weigle oversaw all early aspects of corporate strategy, including defining, communicating and executing the company’s overall business model, and represented Benvenue to the investment community. Mr. Weigle was also a senior executive at numerous healthcare and medical device companies including TherOx, Inc, Cardiac Pathways, Baxter Healthcare and Cardima Corporation. Mr. Weigle also has relevant experience at Johnson & Johnson. Mr. Weigle holds a BA in Political Science from University of California, Berkeley.